123 related articles for article (PubMed ID: 25904005)
1. Selective blockade of mGlu5 metabotropic glutamate receptors is protective against hepatic mitochondrial dysfunction in 6-OHDA lesioned Parkinsonian rats.
Ferrigno A; Vairetti M; Ambrosi G; Rizzo V; Richelmi P; Blandini F; Fuzzati-Armentero MT
Clin Exp Pharmacol Physiol; 2015 Jun; 42(6):695-703. PubMed ID: 25904005
[TBL] [Abstract][Full Text] [Related]
2. Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease.
Ambrosi G; Armentero MT; Levandis G; Bramanti P; Nappi G; Blandini F
Brain Res Bull; 2010 Apr; 82(1-2):29-38. PubMed ID: 20100549
[TBL] [Abstract][Full Text] [Related]
3. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
[TBL] [Abstract][Full Text] [Related]
4. Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist in 6-hydroxydopamine partially lesioned rats reverses abnormal firing of dopaminergic neurons.
Chen L; Zhang QJ; Liu J; Wang S; Ali U; Gui ZH; Wang Y
Brain Res; 2009 Aug; 1286():192-200. PubMed ID: 19545547
[TBL] [Abstract][Full Text] [Related]
5. Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates L-DOPA-induced rotational behavior in a rodent model of Parkinson's disease.
Fuzzati-Armentero MT; Cerri S; Levandis G; Ambrosi G; Montepeloso E; Antoninetti G; Blandini F; Baqi Y; Müller CE; Volpini R; Costa G; Simola N; Pinna A
J Neurochem; 2015 Aug; 134(4):740-7. PubMed ID: 25962878
[TBL] [Abstract][Full Text] [Related]
6. Blockade of metabotropic glutamate receptor 5 attenuates axonal degeneration in 6-hydroxydopamine-induced model of Parkinson's disease.
Zhang JN; Huang YL; Yang HM; Wang Y; Gu L; Zhang H
Mol Cell Neurosci; 2021 Jan; 110():103572. PubMed ID: 33248235
[TBL] [Abstract][Full Text] [Related]
7. Cystic fibrosis transmembrane conductance regulator-associated ligand protects dopaminergic neurons by differentially regulating metabotropic glutamate receptor 5 in the progression of neurotoxin 6-hydroxydopamine-induced Parkinson's disease model.
Wang Y; Gu L; Yang HM; Zhang H
Neurotoxicology; 2021 May; 84():14-29. PubMed ID: 33571554
[TBL] [Abstract][Full Text] [Related]
8. Blockade of metabotropic glutamate receptor 5 protects against DNA damage in a rotenone-induced Parkinson's disease model.
Xia N; Zhang Q; Wang ST; Gu L; Yang HM; Liu L; Bakshi R; Yang H; Zhang H
Free Radic Biol Med; 2015 Dec; 89():567-80. PubMed ID: 26454081
[TBL] [Abstract][Full Text] [Related]
9. Impaired hepatic function and central dopaminergic denervation in a rodent model of Parkinson's disease: a self-perpetuating crosstalk?
Vairetti M; Ferrigno A; Rizzo V; Ambrosi G; Bianchi A; Richelmi P; Blandini F; Armentero MT
Biochim Biophys Acta; 2012 Feb; 1822(2):176-84. PubMed ID: 22119596
[TBL] [Abstract][Full Text] [Related]
10. Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist produces anxiolytic-like effects and reverses abnormal firing activity of projection neurons in the basolateral nucleus of the amygdala in rats with bilateral 6-OHDA lesions.
Chen L; Liu J; Ali U; Gui ZH; Hou C; Fan LL; Wang Y; Wang T
Brain Res Bull; 2011 Feb; 84(3):215-23. PubMed ID: 21255635
[TBL] [Abstract][Full Text] [Related]
11. [Effects of chronic, systemic treatment with metabotropic glutamate receptor 5 antagonist on behavioral activity and neuroprotection in a preclinical rat model of Parkinson's disease].
Chen L; Liu J; Gui ZH; Wang Y; Xiang L
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Jan; 42(1):65-8. PubMed ID: 21355304
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of four pyridine analogs to characterize 6-OHDA-induced modulation of mGluR5 function in rat brain using microPET studies.
Zhu A; Wang X; Yu M; Wang JQ; Brownell AL
J Cereb Blood Flow Metab; 2007 Sep; 27(9):1623-31. PubMed ID: 17299451
[TBL] [Abstract][Full Text] [Related]
13. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism.
Breysse N; Baunez C; Spooren W; Gasparini F; Amalric M
J Neurosci; 2002 Jul; 22(13):5669-78. PubMed ID: 12097518
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats.
Coccurello R; Breysse N; Amalric M
Neuropsychopharmacology; 2004 Aug; 29(8):1451-61. PubMed ID: 15039773
[TBL] [Abstract][Full Text] [Related]
15. Metabotropic glutamate receptor 5 mediates the suppressive effect of 6-OHDA-induced model of Parkinson's disease on liver cancer.
Xi SS; Bai XX; Gu L; Bao LH; Yang HM; An W; Wang XM; Zhang H
Pharmacol Res; 2017 Jul; 121():145-157. PubMed ID: 28455267
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease.
Black YD; Xiao D; Pellegrino D; Kachroo A; Brownell AL; Schwarzschild MA
Neurosci Lett; 2010 Dec; 486(3):161-5. PubMed ID: 20854878
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effects of SCM198 on 6-hydroxydopamine-induced behavioral deficit in rats and cytotoxicity in neuronal SH-SY5Y cells.
Shi XR; Hong ZY; Liu HR; Zhang YC; Zhu YZ
Neurochem Int; 2011 Jul; 58(8):851-60. PubMed ID: 21093517
[TBL] [Abstract][Full Text] [Related]
18. Selective Blockade of the Metabotropic Glutamate Receptor mGluR5 Protects Mouse Livers in In Vitro and Ex Vivo Models of Ischemia Reperfusion Injury.
Ferrigno A; Berardo C; Di Pasqua LG; Siciliano V; Richelmi P; Nicoletti F; Vairetti M
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29360756
[TBL] [Abstract][Full Text] [Related]
19. Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease.
Turle-Lorenzo N; Breysse N; Baunez C; Amalric M
Psychopharmacology (Berl); 2005 Apr; 179(1):117-27. PubMed ID: 15726332
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of metabotropic glutamate receptor 5 inhibits hepatoma development in a neurotoxin rotenone-induced Parkinson's disease model.
Bai XX; Gu L; Yang HM; Xi SS; Xia N; Zhang S; Zhang H
Toxicol Lett; 2018 May; 288():71-81. PubMed ID: 29458170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
